MARKET

ARVN

ARVN

Arvinas
NASDAQ
8.76
-0.32
-3.52%
Pre Market: 8.70 -0.06 -0.68% 05:45 09/10 EDT
OPEN
9.09
PREV CLOSE
9.08
HIGH
9.10
LOW
8.75
VOLUME
25
TURNOVER
0
52 WEEK HIGH
14.51
52 WEEK LOW
6.97
MARKET CAP
572.78M
P/E (TTM)
54.61
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (0831-0904)?
Weekly Report · 3d ago
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
NASDAQ · 6d ago
Weekly Report: what happened at ARVN last week (0824-0828)?
Weekly Report · 08/31 09:18
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Seeking Alpha · 08/28 13:58
Weekly Report: what happened at ARVN last week (0817-0821)?
Weekly Report · 08/24 09:18
Weekly Report: what happened at ARVN last week (0810-0814)?
Weekly Report · 08/17 09:18
Arvinas Price Target Cut to $14.00/Share From $19.00 by Evercore ISI Group
Dow Jones · 08/10 16:28
Arvinas Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 08/10 16:28
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.